Key Takeaways
- • Toscafund Asset Management, led by activist investor Martin Hughes ("the Rottweiler"), has tabled a non-binding £1 billion buyout proposal for Spire Healthcare at 250p per share, which the board indicated it would unanimously recommend if formalized.
- • Spire Healthcare's share price surged 47p to 221p (a 47% gain) on the announcement, valuing the company at £892 million market capitalization, recovering from a five-year low of 142p in March 2026.
- • The proposal follows the collapse of parallel negotiations with private equity firms Bridgepoint and Triton, with Triton withdrawing in March after Spire initiated a strategic review in September 2025.
- • Spire operates 38 private hospitals and over 60 clinics across the UK, serving 1.36 million patients in 2025, with approximately one-third of revenues derived from NHS-funded work such as orthopedic procedures.
- • Toscafund is Spire's second-largest shareholder, and Hughes is a seasoned City figure with a long track record in activist investing and takeover situations.
Summary
Spire Healthcare, Britain's largest private hospital operator, has received a £1 billion non-binding takeover proposal from Toscafund Asset Management, the activist hedge fund led by Martin Hughes. The offer values the company at 250p per share. The Spire board stated it would be "minded to recommend unanimously" the bid if converted to a firm offer, signaling strong board support for the transaction.
The announcement triggered a sharp market response, with Spire's shares jumping 47p to 221p on the day of the announcement—a 47% single-day gain. This recovery is particularly significant given that the stock had declined to a five-year low of 142p in March 2026 before the Toscafund proposal emerged. The current share price reflects a market capitalization of £892 million, below the stated £1 billion proposal valuation, suggesting investor skepticism about deal completion or expectations of a higher bid.
The Toscafund bid arrives following a failed competitive process. Spire launched a formal strategic review in September 2025 and subsequently engaged with multiple bidders, including private equity firms Bridgepoint and Triton. Those negotiations terminated when Triton withdrew in March 2026, leaving Toscafund as the lead contender. Toscafund, already a significant shareholder in Spire, is therefore both a known insider and activist investor with established credibility in acquisition situations.
Spire Healthcare operates a substantial platform with 38 private hospitals and more than 60 clinics distributed across England, Wales, and Scotland. In 2025, the group delivered care to 1.36 million patients. The company was founded in 2007 through the acquisition and rebranding of 25 Bupa hospitals, listed on the stock market in 2014, and has expanded through acquisitions and organic development, including two new-build hospitals in Manchester and Nottingham. Notably, just under one-third of Spire's revenue is derived from NHS-commissioned work, including procedures such as hip and knee replacements, providing a substantial contracted revenue base alongside private patient income.
Martin Hughes, founder of Toscafund in 2000, has earned the epithet "the Rottweiler" for his aggressive approach to activist campaigns and takeover situations, positioning him as an experienced operator in complex healthcare and corporate restructuring scenarios. The formalization of Toscafund's proposal and any competing bids will be critical determinants of final valuation and deal certainty for shareholders.
The announcement triggered a sharp market response, with Spire's shares jumping 47p to 221p on the day of the announcement—a 47% single-day gain. This recovery is particularly significant given that the stock had declined to a five-year low of 142p in March 2026 before the Toscafund proposal emerged. The current share price reflects a market capitalization of £892 million, below the stated £1 billion proposal valuation, suggesting investor skepticism about deal completion or expectations of a higher bid.
The Toscafund bid arrives following a failed competitive process. Spire launched a formal strategic review in September 2025 and subsequently engaged with multiple bidders, including private equity firms Bridgepoint and Triton. Those negotiations terminated when Triton withdrew in March 2026, leaving Toscafund as the lead contender. Toscafund, already a significant shareholder in Spire, is therefore both a known insider and activist investor with established credibility in acquisition situations.
Spire Healthcare operates a substantial platform with 38 private hospitals and more than 60 clinics distributed across England, Wales, and Scotland. In 2025, the group delivered care to 1.36 million patients. The company was founded in 2007 through the acquisition and rebranding of 25 Bupa hospitals, listed on the stock market in 2014, and has expanded through acquisitions and organic development, including two new-build hospitals in Manchester and Nottingham. Notably, just under one-third of Spire's revenue is derived from NHS-commissioned work, including procedures such as hip and knee replacements, providing a substantial contracted revenue base alongside private patient income.
Martin Hughes, founder of Toscafund in 2000, has earned the epithet "the Rottweiler" for his aggressive approach to activist campaigns and takeover situations, positioning him as an experienced operator in complex healthcare and corporate restructuring scenarios. The formalization of Toscafund's proposal and any competing bids will be critical determinants of final valuation and deal certainty for shareholders.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.